Developer docs
API playgroundTry for free, no card

Search company profiles

Zerion Pharma

Full company profile

uuid000dmew

Namestring
Zerion Pharma
Legal namestring
Zerion Pharma A/S
Websiteurl
zerion.eu
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Zerion Pharma A/S is a Copenhagen-based pharmaceutical development company founded in 2019 as a spinout from the University of Copenhagen. The company commercializes a proprietary formulation platform called Dispersome®, an amorphous solid dispersion (ASD) technology that uses beta-lactoglobulin (BLG), a whey-protein-derived excipient, to convert poorly soluble small-molecule drugs into stable amorphous formulations. The technology achieves drug loadings above 50% w/w while maintaining stability, with stable amorphous formulations obtained for more than 80% of drugs tested at that loading; it is compatible with standard spray drying and existing CDMO facilities, and the company's BLG is sourced under a long-term (10+ year) supply agreement with Arla Foods Ingredients as Lacprodan® BLG-100.

Zerion operates an asset-light, B2B licensing and co-development model serving established pharmaceutical companies that face drug solubility and bioavailability challenges. Revenue is generated through technology licensing (license fees, milestone payments, royalties on product sales, with partner exclusivity extending in some cases to 2040), co-development arrangements where Zerion provides formulation R&D and partners fund clinical and commercial activities, and royalty streams from the Hovione joint venture. Its pipeline includes a partnered Ivacaftor Dispersome® program (with Insud Pharma, positive first-in-human bioavailability data in May 2024), an exclusive CBD program with dsm-firmenich, two LATAM-exclusive reformulations with Aché Laboratórios, an oral Trastuzumab program with Bio-Sourcing funded by a €1.3M EUREKA Eurostars grant (Phase I targeted ~2030), and an internal lead program ZN002 (reformulated oncology small molecule) that has demonstrated a 4x bioavailability increase and 75% API reduction in animal studies.

The company's customer base consists almost entirely of large pharmaceutical counterparties — Hovione (global JV, respiratory/nutraceutical), Insud Pharma, Aché, dsm-firmenich, Bayer, Novartis, Ligand Pharmaceuticals (royalty financing), and Bio-Sourcing — together with a research collaboration footprint established through peer-reviewed publications. Zerion holds a patent family covering Dispersome® formulations and processes with protection extending to 2042, and the Dispersome® trademark is registered in its name. Headcount is approximately 13 employees as of January 2025, and the company is privately held with undisclosed financial details.

Short descriptiontext

Zerion Pharma is a Copenhagen-based pharmaceutical development company (founded 2019, spinout from the University of Copenhagen) that licenses its proprietary Dispersome® amorphous solid dispersion platform — using beta-lactoglobulin as a protein-based excipient — to pharmaceutical partners to improve solubility and bioavailability of poorly soluble drugs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug solubility enhancement, amorphous solid dispersion, pharmaceutical formulation technology, drug bioavailability improvement, pharmaceutical technology licensing
Industry1 code
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Formulation Technology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Technology Licensing
TypeLicensing Royalties
Description

Zerion licenses its Dispersome® technology to pharmaceutical companies. Partners gain exclusivity for Dispersome® drug formulations until 2040. Partners pay license fees, milestone fees, and royalties on product sales.

zerion.eu
2Co-development Programs
TypeProfessional Services
Description

Joint development programs with pharmaceutical partners where Zerion develops Dispersome® formulations while partners handle clinical development, manufacturing, and commercialization. Partners cover clinical and development costs.

zerion.eu
3Royalty Income from Joint Ventures
TypeLicensing Royalties
Description

Through the Hovione joint venture, Zerion receives royalties from commercial activities in respiratory delivery, nutraceuticals, and non-exclusive oral dosage form promotions.

zerion.eu
4Royalty Financing
TypeLicensing Royalties
Description

Zerion completed royalty financing with Ligand Pharmaceuticals, receiving upfront capital in exchange for share of future royalty income from Dispersome® technology.

zerion.eu
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Zerion Pharma develops and licenses Dispersome®, a proprietary amorphous solid dispersion platform that uses beta-lactoglobulin (a whey protein excipient) to formulate poorly soluble small-molecule drugs into stable amorphous formulations with drug loadings above 50% w/w. The company runs internal reformulation programs (e.g., ZN002 oncology) and partners with pharmaceutical firms on specific drug products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 4x increase in bioavailability demonstrated in animal studies
+4 more records
Product overview1 text field

Zerion Pharma operates as a pharmaceutical development company offering its proprietary Dispersome® technology platform as the core product. The Dispersome® platform uses beta-lactoglobulin (a whey protein) to formulate poorly soluble small molecule drugs into stable amorphous solid dispersions with high drug loading (>50% w/w) and improved bioavailability. The company develops its own proprietary drug formulations internally (including ZN002 for cancer treatment) while also offering the technology platform to established pharmaceutical companies through partnerships. Key partnered programs include Ivacaftor with Insud Pharma, oral Trastuzumab with Bio-Sourcing, CBD formulations with dsm-firmenich, and drug product improvements with Aché. The technology is compatible with standard spray drying manufacturing processes.

Product and service5 records
1Dispersome® Technology Platform
CategoryPharmaceutical formulation technology
Description

A proprietary amorphous solid dispersion (ASD) platform that uses beta-lactoglobulin (BLG), a natural whey protein excipient, to formulate poorly soluble small-molecule drugs into stable amorphous formulations with drug loadings above 50% w/w. Offered to pharmaceutical partners via feasibility studies, licensing and joint development. Compatible with standard spray drying and CDMO facilities.

2ZN002 Internal Development Program
CategoryInternal drug reformulation program
Description

Zerion's internal pipeline asset: a Dispersome® reformulation of a currently marketed cancer drug that demonstrated a 4x increase in bioavailability and enabled a 75% reduction in active drug amount while maintaining bioequivalence to the originator in animal studies.

3Ivacaftor Dispersome® Formulation (with Insud Pharma)
CategoryPartnered reformulation of marketed drug
Description

Dispersome® formulation of Ivacaftor (a cystic fibrosis treatment) developed in partnership with Insud Pharma. Insud Pharma is responsible for clinical development, GMP manufacturing and global commercialization; Zerion received a worldwide exclusive license for this first Dispersome drug formulation.

4Trastuzumab Oral Formulation (HER2) Program (with Bio-Sourcing)
CategoryPartnered novel biologic oral formulation program
Description

Jointly developed oral formulation of the HER2 monoclonal antibody Trastuzumab for HER2-positive breast cancer, combining Bio-Sourcing's BioMilk™ platform with Zerion's Dispersome® technology. Funded by a €1.3M EUREKA Eurostars grant.

5Cannabidiol (CBD) Dispersome® Formulations (with dsm-firmenich)
CategoryPartnered cannabinoid reformulation program
Description

Improved Cannabidiol (CBD) formulations with enhanced solubility and bioavailability developed under an exclusive partnership with dsm-firmenich, targeting severe pain, inflammation disorders, depression and anxiety, to be made available to the global pharmaceutical industry.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-01-12
Description

Awarded €1.3 million EUREKA Eurostars grant to develop first oral formulation of Trastuzumab for HER2-positive breast cancer. Combines Bio-Sourcing's BioMilk™ platform with Zerion's Dispersome® technology. 36-month project targeting Phase I studies around 2030.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-23
Description

Partnership to improve formulation of two drug products in oncology and neuroscience using Dispersome® technology. Aché granted exclusive rights for Latin America. Products currently marketed with billion-dollar revenue each.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-03
Description

Hovione and Zerion created a joint venture to manage Dispersome® IP portfolio and allocated market rights. Hovione received exclusive global rights for respiratory delivery and nutraceuticals, and non-exclusive license for oral dosage forms. Zerion receives royalties from Hovione's commercial activities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-15
Description

Exclusive partnership to develop improved cannabinoids with enhanced bioavailability. dsm-firmenich conducting clinical PK evaluation of CBD Dispersome® formulations. Product to be made available to global pharmaceutical industry.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2023-06-08
Description

Research collaboration resulting in peer-reviewed publication on Nimodipine Dispersome® formulations showcasing interplay between drug loading and dissolution performance.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2023-06-08
Description

Research collaboration demonstrating Dispersome® technology at drug loadings up to 70% for two different drug compounds. Published in peer-reviewed journal.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-08-29
Description

Collaboration to develop and commercialize Dispersome® formulations of marketed drug products. Zerion develops formulations while Insud Pharma handles clinical development, GMP manufacturing, and global marketing. Zerion granted worldwide exclusive license for first Dispersome® drug formulation (Ivacaftor).

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-02-23
Description

Long-term supply agreement (minimum 10 years) for Lacprodan® BLG-100 pharmaceutical grade beta-lactoglobulin used as excipient in Dispersome® technology. Critical supply chain partnership.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2021-11-24
Description

Extended licensing agreement to exploit Dispersome® technology platform with Rousselot's protein-based excipient capabilities.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers7 records
TypeDirect peer
Description

Portuguese global CDMO with integrated drug substance and drug product services including spray drying and amorphous solid dispersion formulation. Direct peer in formulation/solubility services and a JV partner of Zerion for IP portfolio management and global commercialization.

TypeBroad incumbent
Description

Major US-headquartered global pharma services platform including the OptiForm solution suite for solubility enhancement and amorphous solid dispersions. Comparable in offering ASD-based formulation services, but at much larger scale and as part of a broader CDMO portfolio.

TypeBroad incumbent
Description

Swiss global CDMO that acquired Bend Research/Capsugel, giving it one of the largest ASD and spray-drying formulation service franchises. Comparable in offering pharmaceutical formulation services for poorly soluble compounds but operating across many other modalities at much greater scale.

4DisperSol Technologies
TypeDirect peer
Description

US-based pharmaceutical technology company developing proprietary amorphous solid dispersion platforms to enhance solubility and bioavailability of poorly soluble drugs. Closely aligned technology platform competitor to Zerion's Dispersome® in the same ASD/solubility niche.

TypeDirect peer
Description

US specialty CDMO focused on difficult-to-formulate, poorly soluble small molecule drug products across nanoemulsions, ASDs, and lipid-based systems. Directly comparable as a formulation-focused CDMO serving similar pharma partners seeking solubility solutions.

TypeDirect peer
Description

UK/US CDMO offering formulation development and manufacturing services, with a particular focus on accelerating development of poorly soluble compounds. Comparable in targeting the same poorly-soluble-drug pain point that drives Zerion's partner pipeline.

7Evonik Health Care
TypeBroad incumbent
Description

German specialty chemicals and pharmaceutical excipients/CDMO business offering polymeric excipients (including HPMCAS variants) used in competing ASD formulations alongside formulation CDMO services. Comparable in serving the same solubility/ASD market from an excipient-and-CDMO angle.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Zerion Pharma

Pharmaceutical Formulation Technologyzerion.eu

Zerion Pharma is a Copenhagen-based pharmaceutical development company (founded 2019, spinout from the University of Copenhagen) that licenses its proprietary Dispersome® amorphous solid dispersion platform — using beta-lactoglobulin as a protein-based excipient — to pharmaceutical partners to improve solubility and bioavailability of poorly soluble drugs.

What Zerion Pharma does

Zerion Pharma A/S is a Copenhagen-based pharmaceutical development company founded in 2019 as a spinout from the University of Copenhagen. The company commercializes a proprietary formulation platform called Dispersome®, an amorphous solid dispersion (ASD) technology that uses beta-lactoglobulin (BLG), a whey-protein-derived excipient, to convert poorly soluble small-molecule drugs into stable amorphous formulations. The technology achieves drug loadings above 50% w/w while maintaining stability, with stable amorphous formulations obtained for more than 80% of drugs tested at that loading; it is compatible with standard spray drying and existing CDMO facilities, and the company's BLG is sourced under a long-term (10+ year) supply agreement with Arla Foods Ingredients as Lacprodan® BLG-100.

Zerion operates an asset-light, B2B licensing and co-development model serving established pharmaceutical companies that face drug solubility and bioavailability challenges. Revenue is generated through technology licensing (license fees, milestone payments, royalties on product sales, with partner exclusivity extending in some cases to 2040), co-development arrangements where Zerion provides formulation R&D and partners fund clinical and commercial activities, and royalty streams from the Hovione joint venture. Its pipeline includes a partnered Ivacaftor Dispersome® program (with Insud Pharma, positive first-in-human bioavailability data in May 2024), an exclusive CBD program with dsm-firmenich, two LATAM-exclusive reformulations with Aché Laboratórios, an oral Trastuzumab program with Bio-Sourcing funded by a €1.3M EUREKA Eurostars grant (Phase I targeted ~2030), and an internal lead program ZN002 (reformulated oncology small molecule) that has demonstrated a 4x bioavailability increase and 75% API reduction in animal studies.

The company's customer base consists almost entirely of large pharmaceutical counterparties — Hovione (global JV, respiratory/nutraceutical), Insud Pharma, Aché, dsm-firmenich, Bayer, Novartis, Ligand Pharmaceuticals (royalty financing), and Bio-Sourcing — together with a research collaboration footprint established through peer-reviewed publications. Zerion holds a patent family covering Dispersome® formulations and processes with protection extending to 2042, and the Dispersome® trademark is registered in its name. Headcount is approximately 13 employees as of January 2025, and the company is privately held with undisclosed financial details.

Zerion Pharma firmographics

Firmographics
Name
Zerion Pharma
Legal name
Zerion Pharma A/S
Website
https://zerion.eu
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Zerion Pharma is a Copenhagen-based pharmaceutical development company (founded 2019, spinout from the University of Copenhagen) that licenses its proprietary Dispersome® amorphous solid dispersion platform — using beta-lactoglobulin as a protein-based excipient — to pharmaceutical partners to improve solubility and bioavailability of poorly soluble drugs.
Ownership category
akta.pro rank

Zerion Pharma industry classification

Industry
Product category
Pharmaceutical Formulation Technology
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Drug solubility enhancement
  • Amorphous solid dispersion
  • Pharmaceutical formulation technology
  • Drug bioavailability improvement
  • Pharmaceutical technology licensing

Where Zerion Pharma is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

Zerion Pharma business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Technology Licensing: Zerion licenses its Dispersome® technology to pharmaceutical companies. Partners gain exclusivity for Dispersome® drug formulations until 2040. Partners pay license fees, milestone fees, and royalties on product sales.
  2. Co-development Programs: Joint development programs with pharmaceutical partners where Zerion develops Dispersome® formulations while partners handle clinical development, manufacturing, and commercialization. Partners cover clinical and development costs.
  3. Royalty Income from Joint Ventures: Through the Hovione joint venture, Zerion receives royalties from commercial activities in respiratory delivery, nutraceuticals, and non-exclusive oral dosage form promotions.
  4. Royalty Financing: Zerion completed royalty financing with Ligand Pharmaceuticals, receiving upfront capital in exchange for share of future royalty income from Dispersome® technology.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Zerion Pharma product offering

Product offering

Core offering

Zerion Pharma develops and licenses Dispersome®, a proprietary amorphous solid dispersion platform that uses beta-lactoglobulin (a whey protein excipient) to formulate poorly soluble small-molecule drugs into stable amorphous formulations with drug loadings above 50% w/w. The company runs internal reformulation programs (e.g., ZN002 oncology) and partners with pharmaceutical firms on specific drug products.

Product overview

Zerion Pharma operates as a pharmaceutical development company offering its proprietary Dispersome® technology platform as the core product. The Dispersome® platform uses beta-lactoglobulin (a whey protein) to formulate poorly soluble small molecule drugs into stable amorphous solid dispersions with high drug loading (>50% w/w) and improved bioavailability. The company develops its own proprietary drug formulations internally (including ZN002 for cancer treatment) while also offering the technology platform to established pharmaceutical companies through partnerships. Key partnered programs include Ivacaftor with Insud Pharma, oral Trastuzumab with Bio-Sourcing, CBD formulations with dsm-firmenich, and drug product improvements with Aché. The technology is compatible with standard spray drying manufacturing processes.

Differentiator

Problem solved

Functional benefit

Products and services

  • Dispersome® Technology Platform A proprietary amorphous solid dispersion (ASD) platform that uses beta-lactoglobulin (BLG), a natural whey protein excipient, to formulate poorly soluble small-molecule drugs into stable amorphous formulations with drug loadings above 50% w/w. Offered to pharmaceutical partners via feasibility studies, licensing and joint development. Compatible with standard spray drying and CDMO facilities.
  • ZN002 Internal Development Program Zerion's internal pipeline asset: a Dispersome® reformulation of a currently marketed cancer drug that demonstrated a 4x increase in bioavailability and enabled a 75% reduction in active drug amount while maintaining bioequivalence to the originator in animal studies.
  • Ivacaftor Dispersome® Formulation (with Insud Pharma) Dispersome® formulation of Ivacaftor (a cystic fibrosis treatment) developed in partnership with Insud Pharma. Insud Pharma is responsible for clinical development, GMP manufacturing and global commercialization; Zerion received a worldwide exclusive license for this first Dispersome drug formulation.
  • Trastuzumab Oral Formulation (HER2) Program (with Bio-Sourcing) Jointly developed oral formulation of the HER2 monoclonal antibody Trastuzumab for HER2-positive breast cancer, combining Bio-Sourcing's BioMilk™ platform with Zerion's Dispersome® technology. Funded by a €1.3M EUREKA Eurostars grant.
  • Cannabidiol (CBD) Dispersome® Formulations (with dsm-firmenich) Improved Cannabidiol (CBD) formulations with enhanced solubility and bioavailability developed under an exclusive partnership with dsm-firmenich, targeting severe pain, inflammation disorders, depression and anxiety, to be made available to the global pharmaceutical industry.

Quantifiable outcome

  • 4x increase in bioavailability demonstrated in animal studies
  • +4 more outcomes

Companies that use Zerion Pharma

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Zerion Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Zerion Pharma partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered major, core and supporting.

  • Bio-SourcingmajorStrategic or Co-development Partner · 12 January 2026Awarded €1.3 million EUREKA Eurostars grant to develop first oral formulation of Trastuzumab for HER2-positive breast cancer. Combines Bio-Sourcing's BioMilk™ platform with Zerion's Dispersome® technology. 36-month project targeting Phase I studies around 2030.
  • Aché LaboratórioscoreStrategic or Co-development Partner · 23 January 2025Partnership to improve formulation of two drug products in oncology and neuroscience using Dispersome® technology. Aché granted exclusive rights for Latin America. Products currently marketed with billion-dollar revenue each.
  • HovionecoreStrategic or Co-development Partner · 3 October 2024Hovione and Zerion created a joint venture to manage Dispersome® IP portfolio and allocated market rights. Hovione received exclusive global rights for respiratory delivery and nutraceuticals, and non-exclusive license for oral dosage forms. Zerion receives royalties from Hovione's commercial activities.
  • dsm-firmenichcoreStrategic or Co-development Partner · 15 February 2024Exclusive partnership to develop improved cannabinoids with enhanced bioavailability. dsm-firmenich conducting clinical PK evaluation of CBD Dispersome® formulations. Product to be made available to global pharmaceutical industry.
  • Bayer AGsupportingTechnology or Integration · 8 June 2023Research collaboration resulting in peer-reviewed publication on Nimodipine Dispersome® formulations showcasing interplay between drug loading and dissolution performance.
  • Novartis Pharma AGsupportingTechnology or Integration · 8 June 2023Research collaboration demonstrating Dispersome® technology at drug loadings up to 70% for two different drug compounds. Published in peer-reviewed journal.
  • Insud PharmacoreStrategic or Co-development Partner · 29 August 2022Collaboration to develop and commercialize Dispersome® formulations of marketed drug products. Zerion develops formulations while Insud Pharma handles clinical development, GMP manufacturing, and global marketing. Zerion granted worldwide exclusive license for first Dispersome® drug formulation (Ivacaftor).
  • Arla Foods IngredientscoreTechnology or Integration · 23 February 2022Long-term supply agreement (minimum 10 years) for Lacprodan® BLG-100 pharmaceutical grade beta-lactoglobulin used as excipient in Dispersome® technology. Critical supply chain partnership.
  • Rousselot B.V.supportingTechnology or Integration · 24 November 2021Extended licensing agreement to exploit Dispersome® technology platform with Rousselot's protein-based excipient capabilities.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Zerion Pharma competitors and assessment

Company assessment

Direct peers

  • Hovione: Portuguese global CDMO with integrated drug substance and drug product services including spray drying and amorphous solid dispersion formulation. Direct peer in formulation/solubility services and a JV partner of Zerion for IP portfolio management and global commercialization.
  • DisperSol Technologies: US-based pharmaceutical technology company developing proprietary amorphous solid dispersion platforms to enhance solubility and bioavailability of poorly soluble drugs. Closely aligned technology platform competitor to Zerion's Dispersome® in the same ASD/solubility niche.
  • Ascendia Pharma: US specialty CDMO focused on difficult-to-formulate, poorly soluble small molecule drug products across nanoemulsions, ASDs, and lipid-based systems. Directly comparable as a formulation-focused CDMO serving similar pharma partners seeking solubility solutions.
  • Quotient Sciences: UK/US CDMO offering formulation development and manufacturing services, with a particular focus on accelerating development of poorly soluble compounds. Comparable in targeting the same poorly-soluble-drug pain point that drives Zerion's partner pipeline.

Broad incumbents

  • Catalent: Major US-headquartered global pharma services platform including the OptiForm solution suite for solubility enhancement and amorphous solid dispersions. Comparable in offering ASD-based formulation services, but at much larger scale and as part of a broader CDMO portfolio.
  • Lonza: Swiss global CDMO that acquired Bend Research/Capsugel, giving it one of the largest ASD and spray-drying formulation service franchises. Comparable in offering pharmaceutical formulation services for poorly soluble compounds but operating across many other modalities at much greater scale.
  • Evonik Health Care: German specialty chemicals and pharmaceutical excipients/CDMO business offering polymeric excipients (including HPMCAS variants) used in competing ASD formulations alongside formulation CDMO services. Comparable in serving the same solubility/ASD market from an excipient-and-CDMO angle.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Zerion Pharma social profiles

Digital presence

Zerion Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Zerion Pharma leadership team

Management profile

Number of profiles

Profiles10 records

Zerion Pharma funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Zerion Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zerion Pharma

What does Zerion Pharma do?

Zerion Pharma develops and licenses Dispersome®, a proprietary amorphous solid dispersion platform that uses beta-lactoglobulin (a whey protein excipient) to formulate poorly soluble small-molecule drugs into stable amorphous formulations with drug loadings above 50% w/w. The company runs internal reformulation programs (e.g., ZN002 oncology) and partners with pharmaceutical firms on specific drug products.

Is Zerion Pharma a public or private company?

Zerion Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Zerion Pharma founded?

Zerion Pharma was founded in 2019. It employs 11 to 50 people.

Where is Zerion Pharma based?

Zerion Pharma is headquartered in Copenhagen, Denmark, in the Europe region.

How does Zerion Pharma make money?

Four revenue lines are on record. Technology Licensing is the primary driver. The others are co-development Programs, royalty Income from Joint Ventures and royalty Financing.

Who are Zerion Pharma's main competitors?

Direct peers on record are Hovione, DisperSol Technologies, Ascendia Pharma and Quotient Sciences. Broad incumbents are Catalent, Lonza and Evonik Health Care.

Does Zerion Pharma have an API?

No public API is recorded for Zerion Pharma.

What industry is Zerion Pharma in?

Zerion Pharma's product category is Pharmaceutical Formulation Technology. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmaTimesZerion partner files first EU application for Dispersome‑enabled productA Zerion Pharma partner filed a marketing authorisation application in several European countries for a product using Dispersome technology, the first regulatory submission worldwide. The filing follows Zerion's 2026 funding deal with Ligand Pharmaceuticals and will allow regulators to evaluate beta-lactoglobulin as a new excipient.BioSpaceZerion partner submits first European marketing authorisation application for a Dispersome®-enabled medicinal productA Zerion Pharma partner submitted a marketing authorisation application in several European countries for a Dispersome-enabled medicinal product, the first worldwide regulatory submission for the technology. The application follows a 2026 funding deal with Ligand Pharmaceuticals, and ZERION will receive royalties on sales subject to approval.BioSpaceZerion Pharma completes royalty financing and equity investment transaction with Ligand to advance the Dispersome® technologyZerion Pharma completed a combined royalty financing and equity investment with Ligand Pharmaceuticals to advance its Dispersome technology for improving small drug molecule solubility and bioavailability. Ligand received a share of future royalty income and an equity position, with the technology enabling up to 75% drug dosage reduction.TradingViewZerion Pharma completes royalty financing and equity investment transaction with Ligand to advance the Dispersome® technologyZerion Pharma has completed a combined royalty financing and equity investment transaction with Ligand Pharmaceuticals to advance its Dispersome® technology. Under the agreement, Ligand provided undisclosed funding in exchange for an equity stake and a share of future royalty income from the technology's commercialization. This partnership aims to secure regulatory approval for products utilizing the platform, which enhances drug solubility and bioavailability.Onco'ZineEuropean Biotech Companies to Receive Funding to Develop an Orally Administered anti‑HER2 Antibody for Treatment of Breast CancerBelgium-based Bio-Sourcing and Danish Zerion Pharma have secured €1.3 million in EUREKA Eurostars funding to develop an oral biobetter formulation of trastuzumab (Herceptin) for treating HER2-positive breast cancer. The 36-month project will combine Bio-Sourcing's BioMilk platform with Zerion's Dispersome technology to overcome gastrointestinal barriers, with the aim of advancing to Phase I clinical studies around 2030. The global trastuzumab market is projected to reach USD 4.1 billion by 2030, and an oral formulation could improve patient adherence while reducing healthcare burden compared to current infusion-based treatments.ZerionPress ReleasesBio-Sourcing and Zerion Pharma have been awarded a €1.3 million EUREKA Eurostars grant to develop an oral formulation of Trastuzumab, a monoclonal antibody used to treat HER2-positive breast cancer. The 36-month project will leverage Bio-Sourcing's BioMilk platform and Zerion's Dispersome technology to create an orally deliverable version of the drug, with preclinical validation and Phase I studies targeted for around 2030. The global trastuzumab market is estimated at $4.1 billion by 2030, and an oral formulation could expand patient access while reducing reliance on infusion centers.BioSpaceBio-Sourcing and Zerion Pharma Join Forces to Develop First HER2 Oral Monoclonal Antibody Against Breast CancerBio-Sourcing and Zerion Pharma have been awarded a €1.3 million EUREKA Eurostars grant to develop an oral formulation of Trastuzumab for treating HER2-positive breast cancer, using Bio-Sourcing's BioMilk™ platform and Zerion's Dispersome® technology. The 36-month project will progress the formulation through preclinical validation with the aim of entering Phase I clinical studies around 2030. With the global trastuzumab market estimated at $4.1 billion by 2030, the companies seek to differentiate by offering an oral alternative to infusion-based therapy that could improve patient convenience and expand access to treatment.Business Wire BlogBio-Sourcing and Zerion Pharma Join Forces to Develop First HER2 Oral Monoclonal Antibody Against Breast CancerBio-Sourcing and Zerion Pharma A/S have been awarded EUREKA Eurostars funding for a joint project to develop an oral formulation of Trastuzumab, a monoclonal antibody used to treat HER2-positive breast cancer. The 36-month project will leverage Bio-Sourcing's BioMilk™ platform and Zerion's Dispersome® technology to create an orally deliverable trastuzumab biobetter, with the goal of entering Phase I clinical studies around 2030. The €1.3 million initiative targets a global trastuzumab market estimated at $4.1 billion by 2030, aiming to improve patient convenience and expand access to breast cancer treatment.ZerionPartnering Opportunities with Zerion PharmaZERION Pharma is actively seeking partnership opportunities to license its Dispersome® drug formulation technology, which holds exclusivity until 2040. The company offers a feasibility program for partners to test the technology's application on novel drug compounds and is also looking for distributors or co-development partners for its proprietary formulations.PR NewswireZerion Pharma A/S elects Carl-Åke Carlsson as Chairman of the BoardZerion Pharma A/S announced the election of Carl-Åke Carlsson as its new Chairman of the Board of Directors. Carlsson brings over three decades of pharmaceutical industry experience, including 15 years as CEO of Xellia Pharmaceuticals, where he grew annual sales to USD 300 million and expanded the company to 1,800 employees globally. The appointment is intended to guide Zerion through the commercialization of its Dispersome® technology platform, which improves drug solubility and bioavailability for pharmaceutical partners.